Liang Chen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3902675/publications.pdf

Version: 2024-02-01

1163117 526287 27 894 8 27 citations h-index g-index papers 44 44 44 1251 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	347
2	Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne <i>bla</i> _{KPC-3} Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	334
3	Disease characteristics and management of hospitalised adolescents and adults with community-acquired pneumonia in China: a retrospective multicentre survey. BMJ Open, 2018, 8, e018709.	1.9	33
4	Effects of age, comorbidity and adherence to current antimicrobial guidelines on mortality in hospitalized elderly patients with community-acquired pneumonia. BMC Infectious Diseases, 2018, 18, 192.	2.9	28
5	Assessment of Mortality-Related Risk Factors and Effective Antimicrobial Regimens for Treatment of Bloodstream Infections Caused by Carbapenem-Resistant <i>Enterobacterales</i> Antimicrobial Agents and Chemotherapy, 2021, 65, e0069821.	3.2	25
6	Invasive pulmonary aspergillosis in immunocompetent patients hospitalised with influenza A-related pneumonia: a multicenter retrospective study. BMC Pulmonary Medicine, 2020, 20, 239.	2.0	15
7	Severity and outcomes of influenza-related pneumonia in type A and B strains in China, 2013–2019. Infectious Diseases of Poverty, 2020, 9, 42.	3.7	11
8	Clinical characteristics and outcomes in adult patients hospitalized with influenza, respiratory syncytial virus and human metapneumovirus infections. Expert Review of Anti-Infective Therapy, 2021, 19, 787-796.	4.4	11
9	Impact of early neuraminidase inhibitor treatment on clinical outcomes in patients with influenza B-related pneumonia: a multicenter cohort study. European Journal of Clinical Microbiology and Infectious Diseases, 2020, 39, 1231-1238.	2.9	8
10	Disease burden and prognostic factors for clinical failure in elderly community acquired pneumonia patients. BMC Infectious Diseases, 2020, 20, 668.	2.9	8
11	The Clinical Characteristics and Outcomes of Adult Patients With Pneumonia Related to Three Paramyxoviruses. Frontiers in Medicine, 2020, 7, 574128.	2.6	8
12	Downregulation of FSTL‹1 attenuates the inflammation injury during Streptococcus pneumoniae infection by inhibiting the NLRP3 and TLR4/NF‹ºB signaling pathway. Molecular Medicine Reports, 2019, 20, 5345-5352.	2.4	8
13	The impact of early neuraminidase inhibitor therapy on clinical outcomes in patients hospitalised with influenza A-related pneumonia: a multicenter, retrospective study. BMC Infectious Diseases, 2020, 20, 628.	2.9	6
14	FluA-p score: a novel prediction rule for mortality in influenza A-related pneumonia patients. Respiratory Research, 2020, 21, 109.	3.6	6
15	Comparison of clinical characteristics and outcomes between respiratory syncytial virus and influenza-related pneumonia in China from 2013 to 2019. European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40, 1633-1643.	2.9	6
16	<p>Comparison of the Clinical Characteristics and Severity of Influenza and Non-influenza Respiratory Virus-Related Pneumonia in China: A Multicenter, Real-World Study</p> . Infection and Drug Resistance, 2020, Volume 13, 3513-3523.	2.7	5
17	MiR-222 inhibition alleviates Staphylococcal Enterotoxin B-induced inflammatory acute lung injury by targeting Foxo3. Journal of Biosciences, 2020, 45, 1.	1.1	5
18	Zinc oxide nanoparticles from Corydalis yanhusuo attenuated the mycoplasmal pneumonia in mice through inhibiting the MAPKs signaling pathway. Microbial Pathogenesis, 2020, 147, 104270.	2.9	4

#	Article	IF	CITATION
19	Complications of Cardiovascular Events in Patients Hospitalized with Influenza-Related Pneumonia. Infection and Drug Resistance, 2021, Volume 14, 1363-1373.	2.7	4
20	The severity and risk factors for mortality in immunocompromised adult patients hospitalized with influenza-related pneumonia. Annals of Clinical Microbiology and Antimicrobials, 2021, 20, 55.	3.8	4
21	Flu-IV score: a predictive tool for assessing the risk of invasive mechanical ventilation in patients with influenza-related pneumonia. BMC Pulmonary Medicine, 2022, 22, 47.	2.0	4
22	Human Interferon Inducible Transmembrane Protein 3 (IFITM3) Inhibits Influenza Virus A Replication and Inflammation by Interacting with ABHD16A. BioMed Research International, 2021, 2021, 1-9.	1.9	3
23	Cost Effectiveness of Different Initial Antimicrobial Regimens for Elderly Community-Acquired Pneumonia Patients in General Ward. Infection and Drug Resistance, 2021, Volume 14, 1845-1853.	2.7	3
24	Derivation and validation of a prediction rule for mortality of patients with respiratory virus-related pneumonia (RV-p score). Therapeutic Advances in Respiratory Disease, 2020, 14, 175346662095378.	2.6	2
25	Role of C-X-C motif chemokine ligand 14 promoter region DNA methylation and single nucleotide polymorphism in influenza A severity. Respiratory Medicine, 2021, 185, 106462.	2.9	2
26	MiR-222 inhibition alleviates Staphylococcal Enterotoxin B-induced inflammatory acute lung injury by targeting Foxo3. Journal of Biosciences, 2020, 45, .	1.1	2
27	Prognostic Factors for Cardiovascular Events in Elderly Patients with Community Acquired Pneumonia: Results from the CAP-China Network. Clinical Interventions in Aging, 2022, Volume 17, 603-614.	2.9	2